Group Sales reached a total of 29.4 million euros in 2016, generating a 6 percent growth compared to the previous year. Fourth-quarter sales increased 13 percent compared to the same period of 2015, totaling 7.8 million euros. The results are in line with the accelerated adoption of Medicrea’s patient-specific UNiD technology, notably in the United States where for the entire year, the number of surgeries performed with personalized rods implants have increased by 106 percent compared to 2015.
The 1,000th UNiD™ Rod milestone was achieved in November (almost 1,100 surgeries performed by the end of the year) closely tracking the launch of the company’s Lifetime Warranty on UNiD Rod constructs.
MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA participates in the design, integrated manufacture, and distribution of more than 30 U.S. Food and Drug Administration-approved implant technologies, utilized in more than 100,000 spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA has 160 employees worldwide, which includes 55 at its U.S. subsidiary in New York, N.Y. The company has a manufacturing facility in Lyon, France, housing the development and production of 3D-printed titanium patient-specific implants.